Thiocolchicoside

# Thiocolchicoside ## Overview - **Classification**: Centrally acting muscle relaxant, colchicoside derivative. - **Mechanism**: Acts as a selective GABAA receptor agonist and glycinergic mimetic, inhibiting muscle spasms via supraspinal and spinal levels. ## Primary Indications 1. **Painful Muscle Spasms** - Symptomatic treatment. 2. **Acute Low Back Pain** - Associated with musculoskeletal conditions. 3. **Torticollis** - Neck stiffness with muscle spasms. ## Adult Dosing ### Standard Dosing **Painful Muscle Spasms** (Oral) - **Dose**: **8 mg** - **Frequency**: Once daily (q24h) - **Route**: Oral - **Duration**: Maximum **7 consecutive days** **Painful Muscle Spasms** (Intramuscular - IM) - **Dose**: **4 mg** - **Frequency**: Once daily (q24h) - **Route**: IM - **Duration**: Maximum **5 consecutive days** ### Dose Adjustments - **Renal Impairment**: Use with caution. No specific dose adjustments provided; monitor for adverse effects. - **Hepatic Impairment**: Use with caution. No specific dose adjustments provided; monitor for adverse effects. - **Elderly Patients**: Use with caution. Start at the lowest effective dose; monitor closely for CNS and GI adverse effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **Contraindicated** - **Special Notes**: Due to genotoxicity risk and lack of safety data. ### Infants (1-12 months) - **Dose**: **Contraindicated** - **Special Notes**: Due to genotoxicity risk and lack of safety data. ### Children (1-12 years) - **Dose**: **Contraindicated** - **Special Notes**: Due to genotoxicity risk and lack of safety data. ### Adolescents (13-18 years) - **Dose**: **Contraindicated** for those under 16 years of age. - **Maximum**: **Not recommended** for those 16-18 years due to genotoxicity concerns. Follow adult dosing (max **8 mg/day** orally or **4 mg/day** IM) only if strictly indicated and risks outweigh benefits, with extreme caution. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to thiocolchicoside or colchicine. - **Absolute**: Pregnancy and lactation (breastfeeding). - **Absolute**: Women of childbearing potential not using effective contraception. - **Absolute**: Flaccid paralysis or muscular hypotonia. - **Absolute**: Children and adolescents under **16 years** of age. - **Relative**: History of convulsions or epilepsy. ### Common Adverse Effects - **Common (1-10%)**: Diarrhea, gastralgia, nausea, vomiting. - **Common (1-10%)**: Somnolence, dizziness. - **Serious but Rare**: Convulsions/seizures, liver disorders. ### Key Drug Interactions - **CNS Depressants (e.g., alcohol, sedatives)**: Increased risk of CNS depression (somnolence, dizziness). - **Anticholinergic Drugs**: Potentiates anticholinergic effects. - **Anticoagulants**: Theoretical risk of increased bleeding due to structural similarity to colchicine. ## Monitoring & Follow-up - **Before Treatment**: Assess pregnancy status; confirm effective contraception for women of childbearing potential. - **During Treatment**: Monitor for GI upset, somnolence, dizziness. - **Clinical Signs**: Watch for signs of convulsions/seizures or liver injury (rare). ## Clinical Pearls - 💡 **Short-term use only**: Max **7 days** orally, **5 days** IM, due to genotoxicity concerns. - 💡 Advise patients about potential **somnolence**; caution with driving/operating machinery. - 💡 **Strictly contraindicated** in pregnancy, breastfeeding, and in women of childbearing potential without effective contraception. - 💡 **Contraindicated in all pediatric age groups** (under 16 years) and generally not recommended for adolescents (16-18 years). > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.